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Available online xxxxBackground: Thoracic aortic aneurysm (TAA) is a potentially life-threatening disorder with a strong genetic com-
ponent. The number of genes implicated in TAA has increased exponentially over the last decade. Approximately
20% of patients with TAA have a positive family history. As most TAA remain asymptomatic for a long time,
screening of at risk relatives iswarranted to prevent complications. Existing international guidelines lack detailed
instructions regarding genetic evaluation and family screening of TAA patients.We aimed to develop a consensus
document to providemedical guidance for all health care professionals involved in the recognition, diagnosis and
treatment of patients with thoracic aortic disease and their relatives.
Methods: Amultidisciplinary panel of experts including cardiologists, cardiothoracic surgeons, clinical geneticists
and general practitioners, convened to review and discuss the current literature, guidelines and clinical practice
on genetic testing and family screening in TAA.
Results: There is a lack of high-quality evidence in the literature. This consensus statement, based on the available
literature and expert opinions, summarizes our recommendations in order to standardize and optimize the
cardiogenetic care for patients and families with thoracic aortic disease. In particular, we provide criteria to iden-
tify those patients most likely to have a genetic predisposition, and discuss the preferredmodality and frequency
of screening in their relatives.
Conclusions: Age, family history, aortic size and syndromic features determine who is advised to have genetic
testing as well as screening of ﬁrst-degree relatives. There is a need for more prospective multicenter studies
to optimize current recommendations.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Thoracic aortic aneurysm (TAA) is an abnormal, usually progressive
widening of one or multiple segments of the aorta within the thoracic
cavity. This consensus statement focuses on patients with aneurysms
involving the aortic root and/or ascending aorta without concomitant
aortic valve disease, and on thoracic aortic dissections (Stanford typethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
endations on the cardiogenetic care for patients with thoracic aortic
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connective tissue disorder. Aortic dilatation in patients with repaired or
unrepaired congenital heart disease, e.g. bicuspid aortic valve (BAV), te-
tralogy of Fallot, truncus arteriosus or after the Ross or arterial switch
operation, is not included in this consensus document.
Most patients with TAA are asymptomatic. TAA is usually found ac-
cidentally during imaging studies for other purposes or upon screening
of relatives. TAA can, if left untreated, lead to aortic dissection, rupture
or sudden death. Approximately 20% of patients with TAA have a
positive family history. Familial TAA is often inherited in an autosomal
dominant pattern with incomplete penetrance and variable expressivity
[1]. Despite advancing genetic knowledge and sequencing technologies,
only one quarter of families with TAA receive a molecular diagnosis,
suggesting further locus heterogeneity. Hence, a negative genetic test
result does not exclude a genetic predisposition. Patients with TAA are
more likely to develop aneurysms elsewhere in the arterial tree.
However, the number of studies addressing this issue is limited. Approx-
imately one quarter of patients with TAA have a concomitant abdominal
aortic aneurysm (versus 5% in the general population) [2], and 10% a con-
comitant intracranial aneurysm (versus 1–2% in the general population)
[3]. Relatives of patients with TAA also have an increased risk for
aneurysms beyond the thoracic aorta [1].
The purpose of this document is to provide medical guidance for all
health care professionals involved in the recognition, diagnosis and
treatment of patients with thoracic aortic disease and their relatives.
This consensus statement focuses on the cardiogenetic aspects of care
in thoracic aortic disease including the indications for genetic testing
and guidelines for the cardiovascular screening of relatives. Formore in-
formation on the indications for treatment and the various treatment
options, the authors refer to the latest guidelines of the European
Society of Cardiology (ESC) and the American College of Cardiology/
American Heart Association (ACC/AHA) [4,5].
2. Methods
The National Working Group on BAV & TAA was established in April 2015 at the 3rd
Aortic Symposium in Rotterdam, The Netherlands, and gathers experts with a shared
interest in improving the cardiogenetic care for patients with thoracic aortic disease.
Members were actively recruited from various disciplines and health care institutions, in
order to achieve a broad representation of the ﬁeld. For a complete list of all members of
the working group and their afﬁliations, please see the electronic supplement. The aim
of thisworking groupwas to develop consensus recommendations in order to standardize
and optimize care for patients and families with TAA.
We ﬁrst discussed and agreed upon the deﬁnition of TAA. Following a national
inventory of the major topics among cardiologists and clinical geneticists, three clinical
questions were formulated: What factors are associated with an increased likelihood of
a genetic predisposition for TAA? What genetic tests should be offered for efﬁcient and
cost-effective detection of mutations predisposing to TAA? What cardiovascular screening
of relatives should be recommended? Relevant literature was evaluated to answer these
questions and to formulate concept recommendations. These recommendations were
then discussed at three plenary meetings held between October 2015 and January 2017,
andwere distributed via email to receive input from all working groupmembers. A concept
version of this documentwas provided to theNetherlands Heart Institute (formerly known
as ICIN), theWorking Group Congenital Cardiologyof theNetherlands Society of Cardiology
(NVVC), the Netherlands Association for Cardio-Thoracic Surgery (NVT) and the chairman of
the Dutch General Practitioners' Expert Group on Cardiovascular Diseases (HartVaatHAG).
After the commentswere processed, the consensus documentwas approved by allmembers
of the working group.
3. Results
3.1. Deﬁnition
The deﬁnition of TAA has been the subject of considerable debate
among clinicians and researchers for decades. In the international liter-
ature, different sets of normal reference values for aortic measurements
are provided. Except for the aortic root, these values are often based on
small studies. The expected normal aortic diameters depend on age,
gender, and body surface area. In adults, an aortic diameter of 40 mm
ormore is generally considered dilated [4,6]. In adultswith short staturePlease cite this article as: J.M.A. Verhagen, et al., Expert consensus recomm
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lating Z-scores (number of standard deviations from the predicted
mean) is a helpful way to correlate aortic diameters to body size and
to track aortic growth over time. There are several online tools available
(e.g. www.parameterz.org and www.marfan.org) to calculate Z-scores
using published reference data [7,8]. An aortic diameter Z-score ≥2.0
in adults and ≥3.0 in children is considered enlarged [8,9]. Above the
95th percentile for height, the aortic diameter does not increase linearly
but seems to reach a plateau [10]. In patients with large body size, the
Z-score seems to underestimate the aortic root dilatation and is
therefore unreliable. In adult women with Turner syndrome, the use
of aortic size index is preferred [11].
We recommend to use an absolute threshold of 40 mm for the
deﬁnition of aortic dilatation. In adults with short stature and in chil-
dren, we recommend to use a Z-score of ≥2.0 and ≥3.0, respectively, in
order to adjust for small body size. In adult women with Turner
syndrome, aortic dilatation is deﬁned as aortic size index N2.0 cm/m2.
3.2. Factors increasing the likelihood of a genetic predisposition for TAA
3.2.1. Aortic size
Although there is no scientiﬁc evidence for this contention, we
assume that the contribution of strong genetic factors is larger in patients
withmore severe disease, e.g. an aortic size ≥45mm. Of course, the pres-
ence of other risk factors such as age and hypertension also needs to be
considered (as summarized in Section 3.2.2). We expect that non-
genetic factors are themajor contributors to TAA below 45mm. Patients
with an aortic diameter between 40 and 45mm should be judged on a
case-by-case basis, e.g. depending on age, body size, family history and
conﬁguration of the aorta (e.g. a pear-shaped aortic root).
3.2.2. Traditional cardiovascular risk factors
Ageing and hypertension are important risk factors for developing
TAA [12]. In our experience, the chance of ﬁnding a disease-causing
mutation signiﬁcantly decreases at older age, unless themedical or fam-
ily history provides further clues (see below). Familial disease tends to
occur at relatively younger age [1,13]. A genetic cause should therefore
be suspected in patients with thoracic aortic disease diagnosed before
the age of 50 years, irrespective of the presence of hypertension, and pa-
tients diagnosed between 50 and 60 years without hypertension. There
is no convincing association with other traditional cardiovascular risk
factors. Tobacco use and dyslipidemia may contribute to expansion
(but not formation) of TAA, and aortic dissection [14–16]. Diabetes
mellitus is not clearly associated with thoracic aortic disease [17].
Some studies even suggest a negative association [18]. In contrast to an-
eurysms of the descending thoracic or abdominal aorta, atherosclerosis
is relatively infrequent in ascending TAA [15]. The presence of hyperten-
sion does not exclude a genetic etiology: hypertension can also be a
feature of shared underlying biological processes [19–21].
3.2.3. Positive family history
Family history is a simple yet powerful tool to recognize a genetic
disorder in a family, and should therefore be part of the medical record
of every TAA patient. In TAA patients with a “positive” family history of
TAA or a related disorder an underlying genetic cause is very likely. To
our knowledge, there is no single, generally accepted deﬁnition of a
‘positive’ family history. A positive family history is most commonly
deﬁned as having at least one ﬁrst-degree relative (parents, siblings or
children) with a thoracic aortic aneurysm or dissection. Considering
the small size of modern families, the reduced penetrance of hereditary
thoracic aortic disease, and the association with aneurysms along the
arterial tree (especially abdominal and intracranial aneurysms), we
believe this deﬁnition should be broadened here. We suggest to deﬁne
a positive family history as having at least one ﬁrst- or second-degree
relative with (1) a thoracic aortic aneurysm or dissection, (2) an aneu-
rysm or dissection elsewhere in the arterial tree, diagnosed below 60endations on the cardiogenetic care for patients with thoracic aortic
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tic valve stenosis or bicuspid aortic valve) or patent ductus arteriosus, or
(4) sudden death below 45 years of age.3.2.4. Syndromic features
The presence of syndromic features greatly increases the chance of
ﬁnding a genetic cause [22]. An overview of characteristic or easy recog-
nizable clinical features associated with syndromic forms of thoracic
aortic disease is provided in Table 1.
In summary, we recommend genetic testing in all TAA patients that
fulﬁll at least one of the above mentioned criteria. The results of genetic
tests are not always straightforward andmay be difﬁcult to interpret. In
addition, the outcome of the tests can have important implications for
the patient and his or her relatives. Therefore, the working group rec-
ommends that genetic testing is initiated by a trained professional
(e.g. a clinical geneticist or cardiologist trained in this ﬁeld), to provide
the appropriate pre- and post-test counseling and correct interpretation
of test results.3.3. Genetic testing
TAA represents a genetically heterogeneous group of disorders, that
show signiﬁcant phenotypic overlap. In patients fulﬁlling the revised
Ghent criteria for Marfan syndrome (e.g. combination of thoracic aortic
disease with ectopia lentis), the probability of ﬁnding a FBN1mutation
is high, between66% and 91% [23–25]. Therefore, targeted FBN1 analysis
can be considered in these cases. If no speciﬁc syndromic features
are present, next-generation sequencing (NGS) of multiple genes is
the most efﬁcient and cost-effective method [22]. According to the
European Society of HumanGenetics, this should at least include the fol-
lowing “core genes” ACTA2, COL3A1, FBN1, FLNA,MAT2A,MFAP5,MYH11,
MYLK, NOTCH1, PRKG1, SMAD3, TGFB2, TGFB3, TGFBR1 and TGFBR2 [26].
An overview of the most common TAA-related genes and disorders
with their associated phenotypes is displayed in Table 2.
The statistical power to detect small intragenic copy number vari-
ants using NGS data is suboptimal, though algorithms have improvedTable 1
List ofmost characteristic or easy recognizable clinical features associated with syndromic
forms of thoracic aortic disease.
Craniofacial features Craniosynostosis
Widely spaced eyes (hypertelorism)
Cleft palate or biﬁd uvula
Ocular features Lens subluxation/dislocation (ectopia lentis)
Retinal detachment
High myopia (−6.00 diopters or higher)
Iris hypoplasia or ﬂocculi
Cardiovascular
features
Mitral valve prolapse
Arterial tortuosity
Multiple aneurysms or dissections
Left-sided congenital heart defect or patent ductus arteriosus
Musculoskeletal
features
Pectus excavatum or carinatum
Joint hypermobility or contractures
Recurrent joint subluxations/dislocations
Severe, early-onset osteoarthritis
Severe kyphosis or scoliosis
Cutaneous features Thin, translucent skin with easily visible veins
Hyperelastic skin
Livedo reticularis
Striae at unusual sites/not related to weight gain
Atrophic or wide scars
Other features Short or tall stature
Disproportionately long limbs (dolichostenomelia)
Abnormal long and slender ﬁngers (arachnodactyly)
Spontaneous pneumothorax
Recurrent abdominal wall hernias
Spontaneous rupture of internal organs
Please cite this article as: J.M.A. Verhagen, et al., Expert consensus recomm
disease and their ﬁrst-degree relati..., Int J Cardiol (2017), https://doi.org/considerably over the last few years. Additional high-resolution copy
number analysis might be necessary.
A small subset of patients with TAA carry a (sub)microscopic
deletion or duplication that might, at least partially, have contributed
to aneurysm formation [27–29]. Because such copy number variants
may comprise several consecutive genes with divergent functions,
these patients often display additional abnormalities (“contiguous gene
syndrome”). Chromosomal microarray is therefore recommended in
TAA patients with concurrent neuropsychiatric disorders (e.g. intellec-
tual disability) or multiple congenital anomalies. Furthermore, TAA can
be a rare manifestation of, for example, Alagille syndrome [30], Noonan
syndrome [31] and neuroﬁbromatosis type 1 [32]. Targeted sequencing
of the relevant disease genes should be considered in these cases.
3.4. Cardiovascular screening of relatives
Existing international guidelines are often vague and/or inconsistent
with regard to screening recommendations for relatives of TAApatients.
We experience an urgent need for more detailed instructions to achieve
a more uniform approach to family screening in TAA. However, good
data are scarce.
3.4.1. Whom to screen
The ESC recommends to investigate ﬁrst-degree relatives of patients
with thoracic aortic disease, but mentions only parents and siblings
(and not children) [4]. The ACC/AHA also recommends aortic imaging
for ﬁrst-degree relatives, but adds that imaging of second-degree family
members is reasonable if thoracic aortic disease is identiﬁed in at least
one ﬁrst-degree relative [5].
If a disease-causingmutation has been identiﬁed in the proband, the
working group recommends to offer presymptomatic genetic testing to
relatives. This is best undertaken using a stepwise approach called
“cascade screening”. Cardiovascular screening of mutation carriers
should take place at or in close collaboration with an academic center,
according to gene-speciﬁc management guidelines (see for example
[33,34]).
If no disease-causing mutation has been identiﬁed in the proband,
screening should be offered to all ﬁrst-degree relatives (parents, siblings
and children) of patients fulﬁlling the criteria asmentioned in Section 3.2
and summarized in Fig. 1.
3.4.2. When to screen
The ESC recommends cardiac screening of “healthy” at-risk relatives
every 5 years, but does not mention speciﬁc age ranges. The ACC/AHA
advices imaging every 2 years in familial TAA.
If the familial mutation is known, the working group refers to gene-
speciﬁc guidelines and protocols. If no disease-causing mutation has
been identiﬁed in the proband, the timing of screening depends on the
family history. A positive family history is associated with more aggres-
sive aortic disease, e.g. younger age of onset, higher growth rate and in-
creased risk of developing aortic dissection in relatives, and therefore
warrants closer monitoring [1,35].
In case of familial TAA (see deﬁnition of positive family history in
Section 3.2.3), we suggest to start screening at the age of 25 years or
10 years below the youngest case in the family, if the latter ends up
below 25 years. We assume that clinically relevant disease will rarely
be detected in children or young adults below these age limits, while
the psychological impact of screening should not be underestimated. If
the initial screening reveals no abnormalities, we recommend to con-
tinue screening every 5 years. If the aortic diameters are very small or
remain stable over time, 10-year intervals seem reasonable.We suggest
to discontinue screening by age 65 years. However, if the ﬁrst screening
takes place after the age of 60 years, we recommend at least one follow-
up. In case the screening reveals an abnormality, follow-up should be
adjusted accordingly.endations on the cardiogenetic care for patients with thoracic aortic
10.1016/j.ijcard.2018.01.145
Table 2
Overview of the most common TAA-related genes and disorders with their associated phenotypes.
Genes Disorders (inheritance) Main features
Genes encoding components of the extracellular matrix
BGN Meester-Loeys syndrome (XL) Early-onset aortic aneurysm and dissection, hypertelorism, pectus deformity, joint
hypermobility, contractures, mild skeletal dysplasia
COL1A1 Classical Ehlers-Danlos syndrome (AD) Skin hyperextensibility, dystrophic scarring, joint hypermobility
COL3A1 Vascular Ehlers-Danlos syndrome (AD) Arterial rupture without preceding dilatation, bowel perforations, uterine rupture during
pregnancy, thin and translucent skin, easy bruisability, acrogeria
COL4A5 X-linked Alport syndrome (XL) Progressive renal failure, sensorineural hearing loss, anterior lenticonus
COL5A1 Classical Ehlers-Danlos syndrome (AD) See COL1A1
COL5A2 Classical Ehlers-Danlos syndrome (AD) See COL1A1
EFEMP2 Autosomal recessive cutis laxa type IB (AR) Multiple arterial aneurysms and tortuosity, emphysema, inguinal and diaphragmatic hernia, skin
hyperlaxity, downslanting palpebral ﬁssures
ELN Autosomal dominant cutis laxa 1 (AD), supravalvular aortic stenosis
(AD)
Supravalvular aortic stenosis, peripheral arterial stenosis, skin hyperlaxity, premature aged
appearance, gastrointestinal diverticula, inguinal hernia
FBN1 Marfan syndrome (AD) Mitral valve prolapse, ectopia lentis, pectus deformity, myopia
FBN2 Congenital contractural arachnodactyly (AD) Contractures, arachnodactyly, scoliosis, crumpled ears
LOX Familial thoracic aortic aneurysm 10 (AD) Aortic root aneurysm, ascending aortic aneurysm, bicuspid aortic valve
MFAP5 Familial thoracic aortic aneurysm 9 (AD) Aortic root aneurysm, paroxysmal atrial ﬁbrillation
PLOD1 Kyphoscoliotic Ehlers-Danlos syndrome (AR) Congenital muscle hypotonia, early-onset kyphoscoliosis, joint hypermobility
Genes encoding component of the TGFβ pathway
SKI Shprintzen-Goldberg syndrome (AD) Craniosynostosis, hypertelorism, micrognathia, high palate, arachnodactyly, joint contractures,
hypotonia, developmental delay
SMAD2 No OMIM phenotype Arterial aneurysms and dissections
SMAD3 Loeys-Dietz syndrome 3 (AD) Early-onset osteoarthritis, see further TGFBR1
SMAD4 Juvenile polyposis/hereditary hemorrhagic telangiectasia
syndrome (AD)
Gastrointestinal hamartomatous polyps, cutaneous and mucosal telangiectasia, epistaxis,
arteriovenous malformations
TGFBR1 Loeys-Dietz syndrome 1 (AD) Aortic root aneurysm, arterial aneurysms and dissections, arterial tortuosity, hypertelorism, cleft
palate, biﬁd uvula, pectus deformity, scoliosis, club feet
TGFBR2 Loeys-Dietz syndrome 2 (AD) See TGFBR1
TGFB2 Loeys-Dietz syndrome 4 (AD) Mitral valve prolapse, see further TGFBR1
TGFB3 Loeys-Dietz syndrome 5 (AD) See TGFBR1
Genes encoding component of the vascular smooth muscle cell contractile apparatus
ACTA2 Familial thoracic aortic aneurysm 6 (AD) Iris ﬂocculi, livedo reticularis, premature coronary artery disease and stroke
FLNA Periventricular nodular heterotopia (XL) Periventricular heterotopia, epilepsy, joint hypermobility, patent ductus arteriosus
MYH11 Familial thoracic aortic aneurysm 4 (AD) Aortic dissection, patent ductus arteriosus
MYLK Familial thoracic aortic aneurysm 7 (AD) Ascending aortic aneurysm and dissection
PRKG1 Familial thoracic aortic aneurysm 8 (AD) Early-onset aortic dissection, coronary artery aneurysm and dissection
Other genes and chromosomal abnormalities
FOXE3 Familial thoracic aortic aneurysm 11 (AD) Ascending aortic aneurysm and dissection
GATA5 No OMIM phenotype Bicuspid aortic valve
MAT2A No OMIM phenotype Aortic root aneurysm, ascending aortic aneurysm, bicuspid aortic valve
NOTCH1 Aortic valve disease 1 (AD) Bicuspid aortic valve, calciﬁc aortic stenosis
SLC2A10 Arterial tortuosity syndrome (AR) Generalized arterial tortuosity, arterial aneurysms and stenosis, skin hyperextensibility, joint laxity,
inguinal and diaphragmatic hernia, elongated face, micrognathia
45,X0 Turner syndrome (chromosomal) Short stature, lymphedema, webbed neck, low posterior hairline, low-set ears, amenorrhea,
coarctation of the aorta, bicuspid aortic valve
AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian Inheritance in Man (www.omim.org); XL, X-linked.
4 J.M.A. Verhagen et al. / International Journal of Cardiology xxx (2017) xxx–xxxIn sporadic TAA, we believe a single screening will sufﬁce. However,
if this screening takes place before the age of 40 years, a second screen-
ing might be considered at older age (above 50 years).
3.4.3. How to screen
The ESC and ACC/AHA guidelines do not comment on the imaging
modality of choice.
Transthoracic echocardiography (TTE) is a relatively cheap, widely
available and simple imaging modality for serial measurement of the
aortic root, the most commonly affected site of the thoracic aorta. The
aortic valve can be evaluated simultaneously. However, TTE cannot reli-
ably image all aortic segments, in particular the arch and descending
aorta may be difﬁcult to visualize [36]. Given the high prevalence of
abdominal aortic aneurysms among families with TAA, screening of
the abdominal aorta should be routinely performed [37,38]. Computed
tomography (CT) and magnetic resonance imaging (MRI) are excellent
imaging modalities to visualize both the lumen and wall of the entire
aorta and its side branches. Both techniques are suitable for diagnosis
and monitoring of aortic aneurysms (location, size and extension) and
its relationship to surrounding structures. Major advantages of CT are
the short time required for image acquisition and processing, andPlease cite this article as: J.M.A. Verhagen, et al., Expert consensus recomm
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dinated contrast agents with their potential adverse reactions, and the
radiation exposure. The latter is especially relevant in young individuals,
in particular pregnant women, and serial follow-up. MRI is the imaging
modality of choice in these cases. Major drawbacks of MRI are the rela-
tively limited availability, longer examination times, and higher costs.
Furthermore, the use ofMRI is limited in patientswithmetallic implants
(e.g. pacemakers and occlusion devices) and claustrophobia [36].
In summary, TTE is the primary imaging tool for screening of family
members. We recommend to perform CT or MRI at initial evaluation, to
exclude the presence of aneurysms at areas poorly visualized by TTE.
Furthermore, we encourage routine screening of the abdominal aorta.
If there is a family history of aneurysms, dissections or tortuosity outside
the thoracic aorta, more extensive screening should be considered.
Screening for intracranial aneurysms is usually recommended in fami-
lies with at least two affected [39].
4. Discussion
Patients with TAA often remain asymptomatic until aortic dissection
or rupture occurs with high mortality rates. Preventive treatment savesendations on the cardiogenetic care for patients with thoracic aortic
10.1016/j.ijcard.2018.01.145
Fig. 1. Summary of recommendations. CT, computed tomography; FBN1, ﬁbrillin 1 gene; ID, intellectual disability;MCA,multiple congenital anomalies; MRI,magnetic resonance imaging;
TAA, thoracic aortic aneurysm; TTE, transthoracic echocardiography.
5J.M.A. Verhagen et al. / International Journal of Cardiology xxx (2017) xxx–xxxlives. Therefore, we should be able to identify those individuals at risk of
having or developing thoracic aortic disease. In the absence of detailed
international guidelines, we have put forward recommendations for
family screening and genetic evaluation of TAA patients. Due to the
lack of high level evidence, our recommendations are largely based on
consensus opinion of experts. These may need to be revised and
updated as new data become available. We hope that this consensus
statement will stimulate further national and international discussions.
This document is meant to be a ﬁrst step towards further research and
subsequent development of evidence-based guidelines.
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